Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.51 |
| ▸ | QDPR | P09417 | 2/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 3/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23605276 | 0.86 | QDPR (0.64) | KDM1AQDPRPDE4BSLC6A2SLC6A4 | |
| SCHEMBL21101398 | 0.85 | KDM1A (0.62) | KDM1AQDPRPDE4BSLC6A2SLC6A4 | |
| SCHEMBL23310501 | 0.81 | KDM1A (0.48) | KDM1AQDPRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12716503 | 0.80 | KDM1A (0.55) | KDM1AQDPRPDE4BSLC6A2SLC6A4 | |
| SCHEMBL22279844 | 0.78 | HTR2C (0.54) | KDM1AQDPRPDE4BSLC6A2SLC6A4 | |
| SCHEMBL31063362 | 0.78 | KDM1A (0.54) | KDM1AQDPRPDE4BSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4892688 | 0.77 | HTR2C (0.55) | KDM1AQDPRPDE4BSLC6A2SLC6A4 | |
| SCHEMBL15180853 | 0.76 | KDM1A (0.51) | KDM1AQDPRPDE4BSLC6A2SLC6A4 | |
| SCHEMBL22324870 | 0.75 | ROCK2 (0.46) | KDM1AQDPR | |
| SCHEMBL22324945 | 0.75 | KDM1A (0.42) | KDM1AQDPRPDE4BSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258777-A1 | Selective NR2B Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| US-20160081995-A1 | Selective NR2B Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2016-03-24 | — | — | US | disclosed |
| US-9221796-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| WO-2015105772-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20150191452-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191452-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | KDM1A 4138/4885QDPR 492/4885PDE4B 2485/4885 |
| US-20170258777-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | KDM1A 4138/4885QDPR 492/4885PDE4B 2485/4885 |
| US-20160081995-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | KDM1A 4138/4885QDPR 492/4885PDE4B 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.